Biomarkers predictive of toxicity identified in the review of European Medicines Agency licensing
| Biomarker | Indication | Drug |
|---|---|---|
| DPD deficiency | Colorectal neoplasms Colonic neoplasms Stomach neoplasms Breast neoplasms | Capecitabine (Xeloda and generic drugs: capecitabine accord; capecitabine krka; capecitabine medac and Capecitabine teva) |
| DPD deficiency | Stomach neoplasms | Tegafur/gimeracil/oteracil (Teysuno) |
| HLA-B*5701 allele | HIV infections | Abacavir (Kivexa; Trizivir and Ziagen)* |
| NADPH reductase deficiency | Methemoglobinaemia | Methylthioninium chloride (Methylthioninium chloride Proveblue) |
*HLA-B*5701 allele is predictive of hypersensitivity to abacavir, which is present in three drugs: Kivexa (abacavir/lamivudine); Trizivir (abacavir/lamivudine/zidovudine) and Ziagen (abacavir).